Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban

NCT05515120 is registered in ClinicalTrials.gov with Instituto Mexicano del Seguro Social as lead sponsor.

NCT NCT05515120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05515120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban
Lead sponsor
Instituto Mexicano del Seguro Social
Phase
Phase 2/3
Overall status
Completed
Start date
January 3, 2021
Completion date
July 1, 2022
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant-induced bleeding, pulmonary embolism, venous thromboembolism, venous thromboses